JEWJITSU PEPTIDES: Research roundup on engineered probiotics, neuronal GLUT4 trafficking, and peptide hydrogel materials

A PLoS Pathogens report describes a recombinant Lactobacillus paracasei strain dubbed 3×pBD1/ΔHLJ-27 that secretes multicopy porcine β-defensin-1 (pBD1). The authors report that this engineered probiotic enhanced intestinal morphology and upregulated tight junction proteins, promoted increases in CD4+ T cells and mucosal and systemic immunoglobulins (SIgA and IgG), and reduced mortality, bacterial dissemination, and intestinal pathology in Salmonella Typhimurium infection models. They link protection to suppression of excessive inflammatory signaling and shifts in host–microbiota composition toward beneficial taxa. The study frames this strain as an integrated antimicrobial-plus-immune regulatory approach for livestock agriculture, while experimental scope and long‑term, cross‑species safety and efficacy remain to be further established.

The Cell Reports paper characterizes neuronal activity–dependent plasma translocation of GLUT4 in lateral septum (LS) GABAergic neurons and its role in social familiarity. Mechanistically, neuronal activation triggers CaMKIIα phosphorylation of GLUT4 at Ser243 and Ser254, which enhances Rab10 binding, surface insertion of GLUT4, and glucose uptake. A cell‑permeable TAT‑GLUT4(2D) peptide that disrupts GLUT4–Rab10 binding blocked activity‑dependent trafficking and impaired social familiarity. LS GLUT4 knockdown disrupted social novelty preference and was rescued by wild‑type GLUT4 but not by trafficking‑ or transport‑deficient mutants. In 5xFAD mice the authors observed reduced GLUT4 translocation during social novelty tests, and selective expression of plasma‑localized GLUT4 in LS GABAergic neurons restored neuronal activation and social familiarity measures. These data identify GLUT4 trafficking as a mechanistic node related to social behavior and a potential target in models of Alzheimer’s‑related social impairments; translation to humans and therapeutic implications are not established by this work.

A Chembiochem study reports two enzymatically stable short cationic peptide hydrogelators built from N‑terminal lysine headgroups, non‑coded amino acid spacers, phenylalanine residues, and dodecylamine tails. Both self‑assembled into nanofibrillar hydrogels at physiological pH and showed antibacterial activity against several Gram‑positive and Gram‑negative drug‑resistant strains via membrane permeabilization, transmembrane depolarization, and intracellular ROS generation. One peptide additionally demonstrated anticancer activity in human triple‑negative breast cancer (TNBC) cells with an IC50 reported in the abstract and activation of an extrinsic caspase‑8/caspase‑3 apoptotic pathway plus reversal of epithelial‑to‑mesenchymal transition. The paper notes a structure–function relationship: a central residue with fewer methylene units correlated with stronger anticancer but lower antimicrobial activity. Findings are based on in vitro microbiological and cell assays; further preclinical validation and safety assessment are necessary before considering translational claims.